From Northern Ireland... Big drop in Covid-19 patients thanks to vaccine – chief scientific adviser Professor Ian Young said there are 22 people admitted to hospital for every 1,000 cases of Covid-19, down from 80 per 1,000 in December. https://www.standard.co.uk/news/uk/department-of-health-b949861.html
More Than 99.99% of Vaccinated Americans Have Not Died or Been Hospitalized From Covid: CDC https://www.mediaite.com/news/over-...rom-death-and-hospitalization-from-covid-cdc/ The latest data from the CDC regarding the Covid-19 vaccines is extremely positive for two key factors: protection against death and hospitalization. In fact, the numbers show that for fully-vaccinated Americans, more than 99.99% of them “have not had a breakthrough case resulting in hospitalization or death.” The promising data comes from a CNN analysis of the information collected by the CDC, and the exact figures illustrate exactly how broad the protection have proven to be from the three vaccines approved for emergency use by the FDA: As of Aug. 2, more than 164 million people in the United States were fully vaccinated against Covid-19, according to the CDC. Fewer than 0.001% of those individuals — 1,507 people — died and fewer than 0.005% — 7,101 people — were hospitalized with Covid-19. The CDC also noted that 74% of the reported breakthrough cases — a positive case of Covid-19 in someone who was fully vaccinated — occurred in people who were at least 65 years old. Moreover, out of the 1,507 people who died, one in five of those were “reported as asymptomatic or not related to COVID-19,” the CDC says. The report comes amid heavy media coverage of the highly contagious Delta variant of the virus, as well as concerns about other potential future variants. (More at above url)
160 million people not vaccinated....what percent of 160 million die from Covid About the same percent as vaccinated people
Antibody levels predictive of Moderna's vaccine efficacy -study https://www.reuters.com/business/he...e-modernas-vaccine-efficacy-study-2021-08-10/ Antibody levels are a good predictor for how effective Moderna Inc's (MRNA.O) COVID-19 vaccine is, according to a new study released on Tuesday, a finding which could help speed up future clinical trials for vaccines against the disease. Regulators currently rely on large placebo-controlled studies to determine if a vaccine works, but thestudy, conducted by scientists from the Fred Hutchinson Cancer Research Center, the National Institute of Allergy and Infectious Diseases, Moderna and elsewhere, showed that measuring the antibody levels in vaccine recipients could also determine effectiveness. The study, which has not yet been peer-reviewed, found that the Moderna vaccine was more effective in vaccine recipients with high levels of antibodies. These recipients also reported a lower rate of breakthrough infections after being vaccinated. The study was conducted using data from Moderna's 30,000-participant clinical trial, which started last year and was the basis for the vaccine's authorization. Finding a surrogate measure of efficacy should speed regulators' decisions on vaccine approval even without large placebo-controlled studies, which could be impracticable to carry out if vaccines become widely available, said Peter Gilbert, a researcher at Fred Hutchinson and an author of the study. Combined with data about the Pfizer(PFE.N)/BioNTech and AstraZeneca(AZN.L)vaccines, Gilbert said there has been a "consistent accumulation of evidence" showing that antibodies can be used as an alternate marker for vaccine efficacy.
@jem @wrbtrader @Van_der_Voort_4 https://www.axios.com/coronavirus-v...den-e9be4bb0-3d10-4f56-8054-5410be357070.html New data on coronavirus vaccine effectiveness may be "a wakeup call" Driving the news: The study, conducted by nference and the Mayo Clinic, compared the effectiveness of the Pfizer and Moderna vaccines in the Mayo Clinic Health System over time from January to July. Overall, it found that the Moderna vaccine was 86% effective against infection over the study period, and Pfizer's was 76%. Moderna's vaccine was 92% effective against hospitalization and Pfizer's was 85%. But the vaccines' effectiveness against infection dropped sharply in July, when the Delta variant's prevalence in Minnesota had risen to over 70%. Moderna was 76% effective against infection, and Pfizer was only 42% effective. The study found similar results in other states. For example, in Florida, the risk of infection in July for people fully vaccinated with Moderna was about 60% lower than for people fully vaccinated with Pfizer.
just found that on drudge too... here is the pre print... https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v1 However, in July, the effectiveness against infection was considerably lower for mRNA-1273 (76%, 95% CI: 58-87%) with an even more pronounced reduction in effectiveness for BNT162b2 (42%, 95% CI: 13-62%).
Moderna vaccine shows promise in teen trials https://www.audacy.com/krld/news/national/moderna-vaccine-shows-promise-in-teen-trials Right now, only the Pfizer vaccine has been approved for use amongst teens. Moderna has applied for the same authorization, but the FDA hasn't approved it yet. Some new Phase 3 trials are showing that the Moderna vaccine is just as safe for kids between the ages of 12 to 17, just like the Pfizer vaccine. Their vaccine had the same efficiency at preventing COVID-19 in teens as the Pfizer shot. There's no word when the FDA would give emergency authorization to the Moderna shot for teens.
Who should get a third COVID vaccine shot? About 2.7M immunocompromised Americans, CDC says. https://www.usatoday.com/story/news...2-7-m-immunocompromised-americans/8121138002/ People with severely weakened immune systems should be able to receive a third dose of COVID-19 vaccine, the Centers for Disease Control and Prevention decided Friday afternoon. "This official CDC recommendation – which follows FDA’s decision to amend the emergency use authorizations of the vaccines – is an important step in ensuring everyone, including those most vulnerable to COVID-19, can get as much protection as possible from COVID-19 vaccination," CDC Director Dr. Rochelle Walensky said in a statement. The Food and Drug Administration had decided late Thursday to allow extra shots for people who are immunocompromised, but left it up to the CDC to define exactly who should get the additional doses. A CDC advisory committee spent four hours Friday considering evidence on the safety and effectiveness of extra shots for specific groups of people whose immune systems do not work well, either because of disease or medication. The Advisory Committee on Immunization Practices voted unanimously to offer a third shot to a very narrow band of people: the 2.7% of Americans with the weakest immune systems, who were unlikely to get adequate protection from their initial shots. Extra vaccines should be available to the immunocompromised in the next few days, with a question added about immune status before all vaccinations. The severely immunocompromised are often left unprotected by the two-dose vaccine regimen from Moderna and Pfizer-BioNTech, studies have shown. Roughly 40-44% of people hospitalized with severe COVID-19 infections after vaccination are immunocompromised, the CDC said. Immunocompromised people who catch COVID-19 are also more likely to pass it on to people they live with. Studies summarized Friday suggest an extra dose is safe for most people who are immunocompromised and increases their chance of getting protection against COVID-19. According to the CDC, people who should be considered for a third dose are: Those in active cancer treatment; those who have received organ transplants and are taking immunosuppressive therapy; People who have received CAR-T cell or blood stem cell transplants; People who suffer from moderate or severe primary immunodeficiency (such as those with DiGeorge or Wiskott-Aldrich syndromes); People with advanced or untreated HIV infection; And those taking 20 milligrams or more or corticosteroids like prednisone every day, or alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, severely immunosuppressive cancer chemotherapeutic agents, TNF blockers, and other biologic agents that are immunosuppressive or immunomodulatory. As this is a wide and varied group, patients should discuss concerns and questions with their doctors, the committee said. People will not be required to prove that they have one of these conditions in order to receive a third dose, but simply attest to their status. CDC officials steered away from using the word "booster," emphasizing that the third shot would be part of a normal vaccination course for these severely immunocompromised people. Both the CDC and FDA have determined booster shots are not yet needed by the general population. Although most people will likely need boosters eventually, initial shots are continuing to do an excellent job of protecting people against serious disease and death, Walensky and others say. At a White House briefing Thursday, Jeff Zients, who coordinates the president's COVID-19 task force, said the government has sufficient supply of COVID-19 vaccines to provide the public with boosters as they are needed. The guidance on extra doses only relates to the two most commonly administered vaccines – from Moderna and Pfizer-BioNTech – and not to the Johnson & Johnson vaccine, which has not been studied yet among the immunocompromised. A third dose of the Pfizer-BioNTech vaccine is available for the immunocompromised as young as 12 years old, while Moderna is only allowed for adults, because that vaccine has not yet been authorized for use in minors. For a third dose, people should try to get the same vaccine they received the previous two times, but they could switch between Pfizer-BioNTech and Moderna if necessary, the CDC said. Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, said his agency is developing a solution for J&J recipients. "We do understand the challenges here," Marks told the advisory committee. "We think at least there's a solution here for the very large majority of immunocompromised individuals and we believe that we will probably have a solution for the remainder in the not-too-distant future." At this point, the CDC does not recommend one vaccine over another for people who are immunocompromised. Advocates for people with diabetes expressed concern that their population wasn't included for an extra dose. Having diabetes is known to increase someone's chances of a serious bout with COVID-19, though there's no indication they are at not mounting an immune response to initial vaccine doses. "We would encourage the agencies to ensure that we’re making available additional protections for those patients who we know suffer the worst outcomes from COVID-19," said Dr. Robert Gabbay, Chief Scientific and Medical Officer for the American Diabetes Association. "This includes Americans with diabetes, who would benefit tremendously from protections offered by additional COVID-19 doses.” The list also leaves off people who are over 80, who are known to have weaker immune systems than younger people. About 1% of Americans who have been vaccinated – more than 1 million total – have already gotten themselves an extra shot Dr. Camille Kotton, a committee member and specialist in infectious diseases among the immunocompromised at Massachusetts General Hospital and Harvard Medical School, both in Boston, said she thinks this change will provide third dose access to people who might not otherwise know to get an additional dose. Formally permitting third shots will allow the government to study the effects of these extra doses. "I hope it shows evidence that a booster shot is working for this group," said Philip Felgner, who directs the Vaccine Research and Development Center at the University of California, Irvine. Even after a third dose, people who are severely immunocompromised still need to take precautions to protect themselves against COVID-19, Walensky and others emphasized. Because it is not clear whether they will get adequate protection even after a third dose, people with weakened immune systems should continue to wear masks, maintain social distance, avoid crowds and poorly ventilated indoor spaces with strangers.